Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878179 | 0.82 | PARP1 (0.53) | PARP1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL3903964 | 0.82 | XPO1 (0.51) | PARP1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL25107659 | 0.82 | TPMT (0.45) | MEN1KMT2ASMN1; SMN2HPGDRAB9A | |
| SCHEMBL6556383 | 0.81 | HDAC8 (0.53) | PARP1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL29548994 | 0.81 | KDM4E (0.50) | PARP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14537019 | 0.80 | PARP1 (0.55) | PARP1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL28012959 | 0.80 | MAPT (0.46) | PARP1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL595365 | 0.79 | CES2 (0.53) | PARP1MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL21804751 | 0.79 | CES2 (0.62) | PARP1MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL21861986 | 0.79 | PARP1 (0.50) | PARP1MEN1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113164571-A | Inhibition of ubiquitin-specific peptidase 9X | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020061261-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3010887-A1 | PREPARATION OF CHIRAL 1-METHYL-2,3,4,5-1H-BENZODIAZEPINES VIA ASYMMETRIC REDUCTION OF ALPHA-SUBSTITUTED STYRENES | LEK Pharmaceuticals d.d. (SI) | 2016-04-27 | — | — | EP | disclosed |
| CN-105517994-A | Preparation of chiral 1-methyl-2,3,4,5-1H-benzodiazepines via asymmetric reduction of alpha-substituted styrenes | LEK PHARMACEUTICALS | 2016-04-20 | — | — | CN | disclosed |
| WO-2014202765-A1 | PREPARATION OF CHIRAL 1-METHYL-2,3,4,5-1H-BENZODIAZEPINES VIA ASYMMETRIC REDUCTION OF ALPHA-SUBSTITUTED STYRENES | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202765-A1 | PREPARATION OF CHIRAL 1-METHYL-2,3,4,5-1H-BENZODIAZEPINES VIA ASYMMETRIC REDUCTION OF ALPHA-SUBSTITUTED STYRENES | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-24 | — | — | WO | disclosed |
| EP-0958285-B1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | HOFFMANN LA ROCHE (CH) | 2004-01-07 | — | — | EP | disclosed |
| EP-1183238-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6310208-B1 | Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2000069816-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| CN-1243510-A | Tricyclicbenzo [3] isoindole and benzo (h) isoquinoline | HOFFMANN LA ROCHE (CH) | 2000-02-02 | — | — | CN | disclosed |
| EP-0958285-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030546-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-16 | — | — | WO | disclosed |
| EP-0526535-B1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | ORION YHTYMAE OY (FI) | 1995-09-27 | — | — | EP | disclosed |
| US-5356923-A | 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof | ORION-YHTYMA OY (FI) | 1994-10-18 | — | — | US | disclosed |
| EP-0526535-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE. | ORION YHTYMAE OY (FI) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016303-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | Orion-Yhtymä Oy (FI) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | PARP1 1678/4885MEN1 3166/4885KMT2A 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.